Intellia Therapeutics coverage initiated with underweight rating and $8 target price
NTLA•Barclays initiated coverage of Intellia Therapeutics with an underweight rating and an $8 target price.
Related News
Aon names Denise Perlman reinsurance middle market segment leader
AON•
Yorkville Ives initiates Rivian coverage with outperform rating; target price $20.00
RIVN•
Meta: Yorkville Ives initiates coverage with outperform rating; target price $900
META•
Oracle Corporation: Yorkville Ives initiates coverage with an in-line rating; target price at $155.00
ORCL•
Pegasystems Inc.: Yorkville Ives initiates coverage with outperform rating; target price $43
PEGA•